€
0.04
Sep 29
Business Description
Elite Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US28659T2006
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.84 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -2.84 | |||||
Interest Coverage | 17.29 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 7.63 | |||||
Beneish M-Score | -1.03 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.8 | |||||
3-Year EBITDA Growth Rate | -30.7 | |||||
3-Year EPS without NRI Growth Rate | 125.7 | |||||
3-Year Book Growth Rate | 50 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -25 | |||||
12-1 Month Momentum % | -25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.52 | |||||
Quick Ratio | 2.42 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 130.77 | |||||
Days Sales Outstanding | 90.15 | |||||
Days Payable | 25.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -0.31 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 44.73 | |||||
Operating Margin % | 20.53 | |||||
Net Margin % | -8.98 | |||||
FCF Margin % | 3.51 | |||||
ROE % | -12.54 | |||||
ROA % | -7.88 | |||||
ROIC % | 21.96 | |||||
ROC (Joel Greenblatt) % | -17.37 | |||||
ROCE % | -9.06 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 183.33 | |||||
PS Ratio | 8.21 | |||||
PB Ratio | 12.5 | |||||
Price-to-Free-Cash-Flow | 275 | |||||
Price-to-Operating-Cash-Flow | 137.5 | |||||
EV-to-EBIT | -99.38 | |||||
EV-to-EBITDA | -146.89 | |||||
EV-to-Revenue | 8.28 | |||||
EV-to-FCF | 236.18 | |||||
Price-to-Median-PS-Value | 1.22 | |||||
Earnings Yield (Greenblatt) % | -1.01 | |||||
FCF Yield % | 0.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Elite Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 65.241 | ||
EPS (TTM) (€) | 0 | ||
Beta | 0 | ||
Volatility % | 57.87 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0.002036 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | -25 | ||
52-Week Range (€) | 0.027 - 0.1 | ||
Shares Outstanding (Mil) | 1,011.28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Elite Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Elite Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Elite Pharmaceuticals Inc Frequently Asked Questions
What is Elite Pharmaceuticals Inc(STU:ETF)'s stock price today?
When is next earnings date of Elite Pharmaceuticals Inc(STU:ETF)?
Does Elite Pharmaceuticals Inc(STU:ETF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |